AZN Astrazeneca plc
Price (delayed)
$72.6
Market cap
$225.14B
P/E Ratio
31.98
Dividend/share
$1.55
EPS
$2.27
Enterprise value
$249.95B
AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England.
Highlights
AZN's price to earnings (P/E) is 76% lower than its 5-year quarterly average of 131.6 and 6% lower than its last 4 quarters average of 34.1
Astrazeneca's revenue has increased by 18% YoY and by 6% QoQ
AZN's debt is up by 6% year-on-year but it is down by 4% since the previous quarter
Key stats
What are the main financial stats of AZN
Market
Valuations
Earnings
Shares outstanding
3.1B
Market cap
$225.14B
Enterprise value
$249.95B
Price to earnings (P/E)
31.98
Price to book (P/B)
5.52
Price to sales (P/S)
4.16
EV/EBIT
23.97
EV/EBITDA
14.6
EV/Sales
4.62
Revenue
$54.07B
Gross profit
$43.87B
Operating income
$10B
Net income
$7.04B
EBIT
$10.43B
EBITDA
$17.12B
Free cash flow
$9.99B
Per share
Balance sheet
Liquidity
EPS
$2.27
EPS diluted
$2.25
Free cash flow per share
$3.22
Book value per share
$13.16
Revenue per share
$17.44
TBVPS
$14.78
Total assets
$104.04B
Total liabilities
$63.16B
Debt
$30.3B
Equity
$40.79B
Working capital
-$2.04B
Debt to equity
0.74
Current ratio
0.93
Quick ratio
0.7
Net debt/EBITDA
1.45
Margins
Efficiency
Dividend
EBITDA margin
31.7%
Gross margin
81.1%
Net margin
13%
Operating margin
18.5%
Return on assets
6.8%
Return on equity
17.8%
Return on invested capital
24.4%
Return on capital employed
13.7%
Return on sales
19.3%
Dividend yield
2.13%
DPS
$1.55
Payout ratio
68.3%
AZN stock price
How has the Astrazeneca stock price performed over time
Intraday
-1.22%
1 week
-0.62%
1 month
-4.74%
1 year
7.96%
YTD
10.81%
QTD
-1.22%
Financial performance
How have Astrazeneca's revenue and profit performed over time
Revenue
$54.07B
Gross profit
$43.87B
Operating income
$10B
Net income
$7.04B
Gross margin
81.1%
Net margin
13%
AZN's operating income is up by 22% year-on-year and by 9% since the previous quarter
Astrazeneca's revenue has increased by 18% YoY and by 6% QoQ
AZN's net income is up by 18% year-on-year and by 8% since the previous quarter
The company's gross profit rose by 17% YoY and by 6% QoQ
Growth
What is Astrazeneca's growth rate over time
Valuation
What is Astrazeneca stock price valuation
P/E
31.98
P/B
5.52
P/S
4.16
EV/EBIT
23.97
EV/EBITDA
14.6
EV/Sales
4.62
AZN's price to earnings (P/E) is 76% lower than its 5-year quarterly average of 131.6 and 6% lower than its last 4 quarters average of 34.1
Astrazeneca's EPS has increased by 18% YoY and by 8% QoQ
The stock's price to book (P/B) is 18% less than its 5-year quarterly average of 6.7 and 3.2% less than its last 4 quarters average of 5.7
AZN's equity is up by 4.2% year-on-year
Astrazeneca's revenue has increased by 18% YoY and by 6% QoQ
The stock's price to sales (P/S) is 13% less than its 5-year quarterly average of 4.8 and 8% less than its last 4 quarters average of 4.5
Efficiency
How efficient is Astrazeneca business performance
The company's return on equity rose by 12% YoY and by 7% QoQ
The return on assets is up by 11% year-on-year and by 8% since the previous quarter
Astrazeneca's return on sales has increased by 3.8% YoY and by 2.1% QoQ
Astrazeneca's return on invested capital has increased by 3.4% QoQ and by 2.1% YoY
Dividends
What is AZN's dividend history
DPS
$1.55
Dividend yield
2.13%
Payout ratio
68.3%
Recent dividends
Special dividends are included in TTM DPS and yield
Financial health
How did Astrazeneca financials performed over time
The company's total assets is 65% higher than its total liabilities
The quick ratio rose by 13% year-on-year and by 2.9% since the previous quarter
AZN's current ratio is up by 13% YoY
AZN's debt is 26% smaller than its equity
AZN's debt is up by 6% year-on-year but it is down by 4% since the previous quarter
AZN's debt to equity is down by 5% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.